Volume 5, Supplement 2SupplementA Multidisciplinary Approach to the Management of Hormone-Refractory Prostate CancerSamir S TanejaProstate cancerAndrogen-insensitiveHormone-refractoryMultidisciplinary
Volume 5, Supplement 2SupplementThe Role of the Urologist in Treating Patients with Hormone-Refractory Prostate CancerE David CrawfordChemotherapyHormone-refractory prostate cancerTrainingUrologistsReimbursement
Volume 5, Supplement 2SupplementA Multi-Institutional Pilot Study of Adjuvant Docetaxel for Patients with Prostate Cancer at High Risk for Relapse After Radical ProstatectomyMario A EisenbergerHormone-refractory prostate cancerAdjuvant chemotherapyRadical
Volume 5, Supplement 2SupplementE-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent Nonmetastatic Prostate Cancer...Michael CarducciRobert DreicerProstate cancerDocetaxelEstramustineKetoconazole
Volume 5, Supplement 3SupplementCaP CURE Initiatives and ProjectsHoward R SouleProstate cancerProstate-specific antigenCaP CURE
Volume 5, Supplement 3SupplementA Multidisciplinary Approach to the Management of Hormone-Refractory Prostate CancerSamir S TanejaProstate cancerAndrogen-insensitiveHormone-refractoryMultidisciplinary
Volume 5, Supplement 3SupplementInnovative Therapies for Prostate Cancer TreatmentAnthony TolcherSamira SyedDocetaxelHormone-refractory prostate cancerAntisense oligonucleotides
Volume 5, Supplement 3SupplementA New Paradigm for the Treatment of High-Risk Prostate Cancer: Radiosensitization with DocetaxelParvesh KumarProstate cancerDocetaxelThree-dimensional conformal radiation therapyRadiosensitization
Volume 5, Supplement 3SupplementDocetaxel and Thalidomide as a Treatment Option for Androgen-Independent, Nonmetastatic Prostate CancerWilliam L DahutJames L GulleyPhilip M ArlenWilliam D FiggGregory D LeonardDocetaxelAndrogen-independent prostate cancerThalidomidePalliative
Volume 5, Supplement 3SupplementA Multi-Institutional Pilot Study of Adjuvant Docetaxel for Patients with Prostate Cancer at High Risk for Relapse After Radical ProstatectomyMario A EisenbergerHormone-refractory prostate cancerAdjuvant chemotherapyRadical